Improving immune responses to HIV through vaccination
Optimizing HIV-specific T-cell responses by therapeutic vaccination
This study is working on a new type of vaccine to help your immune system fight HIV better, using special tools to boost your body's response and possibly reduce the virus in your system, so you might not need to rely on daily medications forever.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Massachusetts General Hospital NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project ID | NIH-10756921 on NIH RePORTER |
What this research studies
This research aims to enhance the body's immune response to HIV by developing a therapeutic vaccine that targets the virus more effectively. It focuses on creating 'mosaic' antigens that can stimulate a broader and more robust T-cell response, which is crucial for controlling HIV replication. By optimizing these immune responses, the study seeks to reduce the viral reservoir in patients, potentially allowing for better management of the disease without the need for lifelong antiretroviral therapy. Patients may be involved in trials to assess the effectiveness of this innovative approach.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals living with HIV who are currently on antiretroviral therapy and are interested in exploring new treatment options.
Not a fit: Patients who are not infected with HIV or those who are not on antiretroviral therapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved control of HIV infection and reduce the reliance on lifelong antiretroviral therapy for patients.
How similar studies have performed: Previous research has shown promise in using therapeutic vaccines to enhance immune responses in HIV, but this approach with bioinformatically optimized antigens is relatively novel.
Where this research is happening
Boston, United States
- Massachusetts General Hospital — Boston, United States (Active)
Researchers
- Principal investigator: Juelg, Boris Dominik — Massachusetts General Hospital
- Study coordinator: Juelg, Boris Dominik
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.